Skip to main content

News and FDA-Alerts

Collagen and vitamin drop skin cell
News
10/29/2026
Coleen Stern, MA
The US Department of Health and Human Services has outlined an interim enforcement policy for compounding 6 peptide bulk drug substances while their inclusion on the section 503A bulks list is considered through rulemaking.
The US Department of Health and Human Services has outlined an interim enforcement policy for compounding 6 peptide bulk drug substances while their inclusion on the section 503A bulks list is considered through rulemaking.
The US Department of Health and...
10/29/2026
The Dermatologist
cream
News
10/13/2026
Coleen Stern, MA
Creams containing behenic acid (BA) or ceramide (CER) accelerated recovery of experimentally damaged skin, suggesting that both lipid components may support topical formulations designed to restore barrier function.
Creams containing behenic acid (BA) or ceramide (CER) accelerated recovery of experimentally damaged skin, suggesting that both lipid components may support topical formulations designed to restore barrier function.
Creams containing behenic acid...
10/13/2026
The Dermatologist
FDA Alerts
10/08/2026
Jessica Garlewicz
On October 7, 2026, the US Food and Drug Administration approved remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, as the first treatment for adults with symptomatic dermographism inadequately controlled by H1...
On October 7, 2026, the US Food and Drug Administration approved remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, as the first treatment for adults with symptomatic dermographism inadequately controlled by H1...
On October 7, 2026, the US Food...
10/08/2026
The Dermatologist
GLP-1
News
10/07/2026
Jessica Garlewicz
Glucagon-like peptide-1 receptor agonist treatment was associated with lower all-cause mortality and reduced cardiovascular and psychiatric comorbidity risks among patients with psoriasis and obesity or diabetes.
Glucagon-like peptide-1 receptor agonist treatment was associated with lower all-cause mortality and reduced cardiovascular and psychiatric comorbidity risks among patients with psoriasis and obesity or diabetes.
Glucagon-like peptide-1 receptor...
10/07/2026
The Dermatologist
Smiling woman touching neck
News
10/01/2026
Coleen Stern, MA
Researchers propose an anatomy-driven framework for identifying patients at risk for rapid, region-specific facial volume loss and intervening before visible facial aging progresses.
Researchers propose an anatomy-driven framework for identifying patients at risk for rapid, region-specific facial volume loss and intervening before visible facial aging progresses.
Researchers propose an...
10/01/2026
The Dermatologist
dkin
News
09/30/2026
Coleen Stern, MA
The skin barrier functions as an interconnected physical, chemical, immune, and microbial defense system rather than a single structural layer.
The skin barrier functions as an interconnected physical, chemical, immune, and microbial defense system rather than a single structural layer.
The skin barrier functions as an...
09/30/2026
The Dermatologist
FDA Alerts
09/28/2026
Riya Gandhi, MA
FDA has expanded the indication for baricitinib (Olumiant) to include adolescents aged 12 years and older with severe alopecia areata, based on results from the Phase 3 BRAVE-AA-PEDS trial.
FDA has expanded the indication for baricitinib (Olumiant) to include adolescents aged 12 years and older with severe alopecia areata, based on results from the Phase 3 BRAVE-AA-PEDS trial.
FDA has expanded the indication...
09/28/2026
The Dermatologist
Global travel
News
09/03/2026
Jessica Garlewicz
Investigators assessed trends in psoriasis cases, effects on quality of life, and associated economic costs.
Investigators assessed trends in psoriasis cases, effects on quality of life, and associated economic costs.
Investigators assessed trends in...
09/03/2026
The Dermatologist
FDA Alerts
08/31/2026
Coleen Stern, MA
For dermatologists and patients, this approval provides a new alternative targeting the JAK-mediated inflammation that damages the muscles and skin in dermatomyositis to control both cutaneous and systemic manifestations.
For dermatologists and patients, this approval provides a new alternative targeting the JAK-mediated inflammation that damages the muscles and skin in dermatomyositis to control both cutaneous and systemic manifestations.
For dermatologists and patients,...
08/31/2026
The Dermatologist
FDA Alerts
08/07/2026
Jessica Garlewicz
The US Food and Drug Administration (FDA) has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma.
The US Food and Drug Administration (FDA) has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma.
The US Food and Drug...
08/07/2026
The Dermatologist